Molecular prognostic indicators in breast cancer

European Journal of Surgical Oncology

Volumn 28, Issue 5, 2002, Pages 467-478

  Rogers, C E ^a   Loveday, R L ^a   Drew, P J ^a   Greenman, J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Breast cancer; Oncogene; Prognostic markers; Proliferation; Protease

Indexed keywords

CATHEPSIN D; CELL MARKER; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE B; GENE PRODUCT; KI 67 ANTIGEN; NUCLEOSIDE DIPHOSPHATE KINASE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; PROTEINASE; TENASCIN; UROKINASE;

ANIMAL CELL; BREAST CANCER; CELL PROLIFERATION; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; HEALTH CARE QUALITY; HUMAN; HUMAN CELL; MARKER GENE; MEDICAL ASSESSMENT; MEDICAL EDUCATION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE NEU; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFECT; REVIEW;

EID: 0036704492     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1258     Document Type: Review

References (77)

1. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42: 2025-31.
2. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990; 335: 1565-8.
3. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
4. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study wi0th long term follow up. Histopathology 1991; 19: 403-10.
5. Sjogren S, Inganas M, Norberg T et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-82.
6. Alsabeh R, Wilson CS, Ahn CW, Vasef MA, Battifora H. Expression of Bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 1996; 9(4): 439-44.
7. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO. Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 1998; 76: 22-6.
8. van Slooten HJ, Clahsen PC, van Dierendonck JH et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of per-operative chemotherapy. Br J Cancer 1996; 74(1): 78-85.
9. Le MG, Mathieu M-C, Douc-Rasy S et al. C-myc, p53 and Bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between Bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 1999; 84: 562-7.
10. Teixeira C, Reed JC, Pratt MAC. Oestrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55(17): 3902-7.
11. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998; 52: 79-98.
12. Lane DP. Cancer. p53, the guardian of the genome. Nature 1992; 358: 15-16.
13. Bray SE, Schorl C, Hall PA. The challenge of p53: linking biochemistry, biology and patient management. Stem Cells 1998; 16: 248-60.
14. Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80(12): 1968-73.
15. van Slooten HJ, van de Vijver MJ, van de Velde CJK, van Dierendonck JH. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 1998; 77(5): 789-96.
16. Harbeck N, Dettmar P, Thomssen C et al. Risk group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999; 80: 419-26.
17. Berns EMJJ, Klijn JGM, van Putten WLJ et al. P53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 1998; 16(1): 121-7.
18. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates electively in p53-deficient human tumour cells. Science 1996; 274: 373-6.
19. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177-82.
20. Paterson MC, Deitrich KD, Danyluk J et al. Correlation between C-erb-B2 amplification and risk of recurrent disease, in node-negative breast cancer. Cancer Res 1991; 51 (2): 556-67.
21. Charpin C, Garcia S, Bouvier C et al. C-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 1987; 75(11): 1667-73.
22. Dittadi R, Brazzale A, Pappagallo G et al. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 1997; 17(2B): 1245-7.
23. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterised by florescence in situ hybridisation: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15(8): 2894-904.
24. Cobleigh MA, Vogel CL, Tripathy D et al. Efficacy and safety of Herceptin® (humanised anti-HER-2 antibody) as a single agent in 222 women with HER2 over expression who relapsed following chemotherapy for metastatic breast cancer. J Clin Oncol 1999; 17(9): 2639-48.
25. Slamon DJ, Leyland-Jones B, Shak S. Addition of Herceptin® (humanised anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized multinational controlled phase III trial. Cancer Proc Am Soc Clin Oncol 1998; 17: 98a.
26. Barnes DM, Gillet CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998; 52: 1-15.
27. Gillet CE, Fantl V, Smith R et al. Amplification and over expression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54(7): 1812-7.
28. Alle KM, Henshall SM, Field AS, Sutherland RI. Cyclin D1 protein is expressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 1998; 4: 847-54.
29. van Diest PJ, Michalides RJAM, Jannink I et al. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol 1997; 150(2): 705-11.
30. Kenny FS, Hui R, Gee JMW et al. Over expression of cyclin D1 messenger RNA predicts poor prognosis in oestrogen receptor-positive breast cancer. Clin Cancer Res 1999; 5(8): 2069-76.
31. Nakopoulou L, Tsitsimelis D, Lazaris ACh et al. Nm23, c-erbB2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters. Cancer Detect Prev 1999; 23(4): 297-308.
32. Steeg PS, Bevilacqua G, Kopper L et al. Evidence of a novel gene associated with low tumour metastatic potential. J Natl Cancer Inst 1988; 80(3): 200-4.
33. Rosengard AM, Krutzsch HC, Shearn A et al. Reduced nm23/awd protein in tumour metastasis and aberrant Drosophila development. Nature 1989; 342: 177-80.
34. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 1989; 49(18): 5185-90.
35. Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ, Silcocks PB. Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 1993; 85(9): 727-31.
36. Charpin C, Garcia S, Bonnier P et al. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays. J Pathol 1998; 184: 401-7.
37. Heimann R, Lan F, McBride R, Hellman S. Separating favourable from unfavourable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res 2000; 60: 298-304.
38. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ. Urokinase plasminogen activator in different subgroups of patients with breast cancer. Cancer 1994; 74: 2276-80.
39. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase plasminogen activator, a marker for aggressive breast carcinomas. Cancer 1988; 62: 531-3.
40. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998; 44(6): 1177-83.
41. Grøndahl-Hansen J, Christensen JJ, Rosenquist C et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-I in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53(11): 2513-21.
42. Janicke F, Schmitt M, Pache L et al. Urokinase (uPA) and its inhibitor PAI-I are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.
43. Spyratos F, Martin PM, Hacene K et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84: 1266-72.
44. Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius V-M, Blomqvist C. Cathepsin D, urokinase plasminogen activator and type-I plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and-relations to tenascin-C and other factors. Br J Cancer 1999; 80: 167-74.
45. Grøndahl-Hansen J, Agerlin N, Munkholm-Larsen P, Neilsen LS, Dombernowsky P, Danø K. Sensitive and specific enzyme-linked immunosorbant assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42-51.
46. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. New Engl J Med 1990; 322: 297-302.
47. Spyratos F, Maudelonde T, Brouillet J-P et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989; 2(8672): 1115-18.
48. Duffy MJ, Brouillet J-P, Reilly D et al. Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem 1991; 37(1): 101-4.
49. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder MJ, van Putten WLJ, Klijn JGM. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79(2): 300-7.
50. Jahkola T, Toivonen T, Virtanen I et al. Tenascin-C expression in the invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 1998; 78(11): 1507-13.
51. Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF-7 cells and fibroblasts. Cancer Res 1989; 49(15): 4322-5.
52. Gould VE, Koukoulis GK, Virtaren I. Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differ Dev 1990; 32(3): 409-16.
53. Jahkola T, Toivonen T, von Smitten K, Blomqvist C, Virtanen I. Expression of tenascin in the invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996; 69(6): 445-7.
54. Joachim EE, Athanassiadou SE, Kamina S, Carassavoglou K, Agnantis NJ. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2, oncoprotein, p53, steroid receptor status and proliferative indices. Anticancer Res 1998; 18: 1665-70.
55. Garbett EA, Reed MWR, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer 1999; 81(2): 287-93.
56. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K. Expression of matrix metalloproteinase 9 in vascular pericytes in human breast cancer. Lab Invest 1997; 77(4): 345-55.
57. Rha SY, Kim JH, Roh JK et al. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat 1997; 43(2): 175-81.
58. Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-I in paired primary tumours and brain metastases. Clin Cancer Res 1999; 5(12): 4028-33.
59. Hedley DW, Friedlander ML, Taylor IW. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-5.
60. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
61. Gerdes J, Lelle RJ, Pickartz HL et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 1986; 39: 977-80.
62. Cattoretti G, Becker MHG, Key G. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-63.
63. Baak JPA, van Dop H, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374-82.
64. Isola JJ, Helin HJ, Helle MJ, Kallionoemi O. Evaluation of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer 1990; 65: 1180-4.
65. Veilh P, Chevillard S, Mosseri V, Donatini B, Magelenat H. Ki-67 index and S phase fraction in human breast carcinomas. Am J Clin Pathol 1990; 94: 681-6.
66. Sahin AA, Ro J, Ro JY et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Cancer 1991; 68: 549-57.
67. Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki-67 compared to S phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996; 2(3): 585-92.
68. Jansen RLH, Hupperets PSGJ, Arends JW et al. MIB-I labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 1998; 78(4): 460-5.
69. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Am J Clin Pathol 1995; 104: 42-9.
70. Dettmar P, Harbeck N, Thomssen C et al. Prognostic impact of proliferation-associated factors MIB-I (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 1997; 75(10): 1525-33.
71. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustaffson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.
72. Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor β in breast cancer. Br J Surg 2000; 87: 405-9.
73. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000; 24: 145-55.
74. Speirs V, Parkes AT, Kerin MJ et al. Coexpression of estrogen receptor α and β: poor prognostic factors in breast cancer. Cancer Res 1999; 59: 525-8.
75. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of oestrogen receptor βmRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999; 59: 5421-4.
76. Järvinen TAH, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156(1): 29-35.
77. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. New Engl J Med 1992; 326(26): 1756-61.